Ignite Creation Date:
2024-05-05 @ 5:24 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00440245
Status:
COMPLETED
Last Update Posted:
2020-03-27
First Post:
2007-02-22
Brief Title:
Bronchoprotection of Salbutamol in Asthma and Chronic Obstructive Pulmonary Disease
Sponsor:
University of Saskatchewan
Organization:
University of Saskatchewan
Study Overview
Official Title:
Bronchoprotection of Salbutamol in Asthma and COPD
Status:
COMPLETED
Status Verified Date:
2020-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will investigate potential differences in how two puffs of salbutamol protects airway smooth muscle from contracting in people with asthma and chronic obstructive pulmonary disease COPD
Detailed Description:
In asthma the administration inhalation of a selective β2 receptor agonist eg salbutamol prior to methacholine challenge has been shown to shift the dose response curve to the right and bronchoprotect the airway against airway smooth muscle contraction The extent of β2 receptor agonist bronchoprotection in COPD is unknown
Airway hyperresponsiveness AHR to direct acting agents such as histamine and methacholine is a feature of both asthma and COPD In asthma the abnormality leading to AHR is believed to be due to changes in airway smooth muscle eg hypertrophy hyperplasia contractile apparatus whereas in COPD the AHR is likely due to structural or geometric changes
The investigators hypothesize that the bronchoprotection afforded by salbutamol against methacholine challenge will be greater in asthma than in COPD due to differences in underlying airway abnormalities
Airway hyperresponsiveness AHR to direct acting agents such as histamine and methacholine is a feature of both asthma and COPD In asthma the abnormality leading to AHR is believed to be due to changes in airway smooth muscle eg hypertrophy hyperplasia contractile apparatus whereas in COPD the AHR is likely due to structural or geometric changes
The investigators hypothesize that the bronchoprotection afforded by salbutamol against methacholine challenge will be greater in asthma than in COPD due to differences in underlying airway abnormalities
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None